Replies to post #97522 on NanoViricides Inc. (NNVC)

[changes_iv]

daBoze, we are constructing a railway that will take FluCide to the Clinical Trials in Australia (2015) and ultimately to FDA review/market. However, FluCide GLP full tox study, is the one station in which the "train of therapeutic drugs" will not be slowing down or stopping for again. The BigKahuna explains...

Under 505b, tox for FluCide becomes tox for everything that follows. For the second tox following FluCide, they will only need to show bioequivalence, that is, a bridge study would be required to demonstrate that a system processes EbolaCide, DengueCide, X-Cide, in the same way as FluCide. Since FluCide will most probably already be in clinical trials, the second and maybe third X-Cide for clinical trials will need only a bridge study in Phase 1 to advance to Phase 2/3, again that would be an abbreviated PK study showing bioequivalence in processing versions of nanomicelles. ~ BigKahuna

Every key step/milestone that is realized will reassure investors and should be accompanied by a rise in pps. I'd like to think $30 pps by Christmas. People will say not possible. If we are successful, effective, with the EbolaCide candidate I would say higher than $30.

Drugs to FDA review/market will move faster and with it the climb in pps.